A clinical comparison of cinoxacin and nalidixic acid in the treatment of urinary tract infection.
In a single blind clinical study of 50 patients with urinary tract infections 250 mg. cinoxacin were compared to 1 g. nalidixic acid 4 times daily. Both drugs produced similar improvement in symptomatic response during therapy and were equally effective in eradicating the causative pathogens. In the 5 of 9-day post-therapy followup 4 patients from the cinoxacin group became reinfected compared to 1 from the nalidixic acid group. Side effects were reported by twice as many patients in the nalidixic acid group. It is concluded that cinoxacin is an effective drug for the treatment of uncomplicated urinary tract infections.
D000328:Adult; D002493:Central Nervous System Diseases / Q000139:chemically induced; D002937:Cinoxacin / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004927:Escherichia coli Infections / Q000188:drug therapy*; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D009268:Nalidixic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D011724:Pyridazines / Q000627:therapeutic use*; D012008:Recurrence; D014552:Urinary Tract Infections / Q000097:blood / Q000188:drug therapy*
D011724:Pyridazines; D009268:Nalidixic Acid; D002937:Cinoxacin